The latest cohort of the Drive accelerator program has unveiled ten promising startups that aim to advance life sciences. This initiative, jointly led by MassBio and SCbio, seeks to empower scientific founders with the resources necessary for sustained success. Among the selected participants, five represent biotech companies while the other five are tech-focused, addressing a range of therapeutic modalities such as small molecules, antibodies, gene editing, gene therapy, oncolytic viruses, and cell therapy.
Geographic Distribution of Startups
Of the ten selected enterprises, seven are situated in the United States, including four based in Massachusetts. This geographical concentration underscores the region’s reputation as a thriving hub for life sciences innovation.
Massachusetts’ MassBio will manage the techbio segment of the program, focusing on innovative therapeutic approaches to combat pressing health challenges. These include glioblastoma, pancreatic cancer, Parkinson’s disease, and drug resistance, utilizing cutting-edge techniques like generative protein design and virtual cell modeling.
Conversely, the biotech cohort, supervised by SCbio, will tackle complex conditions such as ALS, Alzheimer’s disease, a rare pediatric neurological disorder, liver cancer, and obesity. The diverse range of targets highlights the ambitious nature of these startups.
Insights from Program Leaders
Kendalle Burlin O’Connell, CEO of MassBio, emphasized the significance of the techbio cohort in addressing some of medicine’s toughest challenges. In her remarks about the program, she noted that progress in these areas has been slow due to funding difficulties, particularly at the pre-seed and seed stages. The Drive program aims to bridge this gap, helping these startups reach their next crucial milestones.
Similarly, James Chappell, CEO of SCbio, expressed confidence in the biotech cohort, stating that the founders are committed to solving critical issues in neuroscience, metabolic diseases, and cancer. His organization is prepared to support these innovators in delivering their treatments to those in need.
Eligibility and Program Structure
To qualify for the Drive program, startups must not have secured more than $1.5 million in equity-based funding at the time of application. Moreover, they must possess intellectual property rights to their technology or be able to negotiate a license through an agreement.
The Drive program spans eight weeks and is offered at no cost to selected companies. Participants will engage in six industry-specific curriculum modules led by seasoned experts and benefit from weekly mentorship sessions. Additionally, networking opportunities will be available, culminating in in-person demo days in both Boston and Charleston, South Carolina.
Unique Opportunities for Graduates
An exciting aspect of this cohort is a partnership with the ADA Forsyth Institute, which will provide one graduate from the fall cohort with a sponsored lab bench for an entire year at their facility in Somerville, Massachusetts. Other graduates will also have access to a discounted rate, offering them invaluable resources for further development.
Since its inception in 2022, the Drive program has successfully supported 70 early-stage companies, which collectively raised $137 million in funding and generated nearly 100 jobs post-completion.
Conclusion
The selection of these ten startups for the Drive accelerator program highlights a commitment to fostering innovation in the life sciences sector. By providing essential resources and guidance, MassBio and SCbio are equipping these emerging companies to tackle some of the most pressing healthcare challenges. This initiative not only contributes to scientific advancement but also enhances economic growth within the biotechnology ecosystem.
- Key Takeaways:
- Ten startups selected for the Drive accelerator program.
- Focus on diverse therapeutic modalities including gene therapy.
- Program offers mentorship, networking, and unique lab opportunities.
- Emphasis on addressing critical health challenges in neuroscience and cancer.
- Significant funding raised by past participants demonstrates the program’s impact.
Read more → www.biospace.com